Abstract

Objective: Catheter ablation combined with left atrial appendage closure (LAAC) has emerged as a promising strategy for atrial fibrillation (AF) patients at high risk for stroke or with contraindications for oral anticoagulants (OACs). But the evidence for the long-term safety and efficacy of a combined procedure using cryoballoon ablation (CBA) with LAAC is still insufficient.Methods: From October 2015 to December 2017, a total of 76 consecutive non-valvular, drug-refractory AF patients who underwent a combined procedure of CBA and LAAC are included. Peri- and post-procedural safety and efficacy were evaluated through scheduled follow-ups and transesophageal echocardiography (TEE).Results: A total of 74 patients (97.4%) underwent the combined procedure and achieved instant pulmonary vein isolation and satisfactory LAAC. With a mean follow-up time of 23.7 ± 11.0 months, the recurrence of atrial arrhythmia was recorded in 35 patients (48.0%). In addition, a survival analysis shows a non-significant higher recurrence in persistent AF (p = 0.48). The overall OAC withdrawal rate was 97.2%, and one patient (1.4%) had a lethal hemorrhagic stroke while on single antiplatelet therapy. For safety concerns, the overall mortality was 2.7%, which resulted from one case of myocardial infarction on OAC and one hemorrhagic stroke, as mentioned. No other major hemorrhagic events occurred. Among the 72 patients (94.7%) who underwent TEE, one patient (1.4%) had device-related thrombosis and one patient (1.4%) had prominent residual flow (over 3 mm). Both were prescribed long-term OACs without severe complications occurring.Conclusions: Combining CBA with LAAC in a single procedure achieved considerable long-term safety and efficacy, providing a promising strategy for AF management.

Highlights

  • Zhongyuan Ren 1,2†, Jingying Zhang 1†, Songyun Wang 3, Peng Jia 1, Xiang Li 1, Jun Zhang 1, Rong Guo 1, Hailing Li 1, Shuang Li 1, Haotian Yang 1, Yixing Zheng 1, Weilun Meng 1, Yawei Xu 1* and Dongdong Zhao 1*

  • The overall oral anticoagulants (OACs) withdrawal rate was 97.2%, and one patient (1.4%) had a lethal hemorrhagic stroke while on single antiplatelet therapy

  • The overall mortality was 2.7%, which resulted from one case of myocardial infarction on OAC and one hemorrhagic stroke, as mentioned

Read more

Summary

Methods

From October 2015 to December 2017, a total of 76 consecutive non-valvular, drug-refractory AF patients who underwent a combined procedure of CBA and LAAC are included. October 2015 to December 2017, we investigated patients with documented drug-refractory, non-valvular AF who underwent the combined procedure of CBA and LAAC. Patients are considered eligible for the combined procedure if they meet at least one of the following criteria: Frontiers in Cardiovascular Medicine | www.frontiersin.org. The LAAC device was implanted instantly after CBA. Three types of LAAC devices were used: the Lefort Technology Co., Ltd., Shanghai, China), and WATCHMAN devices (WATCHMAN, Boston Scientific, MA, USA) (Figure 3). 39, 17, and 20 patients were given carefully delivered in the LAA through the access system and deployed at the ostium of the LAA by retracting the access sheath

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call